Sirpiglenastat is under clinical development by Dracen Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirpiglenastat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DRP-104 is under development for the treatment of oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer, hormone refractory (castration resistant, androgen-independent) prostate cancer, advanced solid tumors, laryngeal cancer and metastatic non small cell lung cancer. It developed based on immuno-metabolism platform. It is administered through intravenous and subcutaneous routes. The drug candidate has active moiety of DON(6-Diazo-5-oxo-L-norleucine) which acts against glutamine.
It was under development for treatment of recurrent, unresectable, or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Dracen Pharmaceuticals overview
Dracen Pharmaceuticals, Inc., is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients. The company is headquartered in United States.
For a complete picture of Sirpiglenastat’s drug-specific PTSR and LoA scores, buy the report here.